Advancing Supportive Oncology Research

Developing an Investigational Approach to Cancer Therapy–Induced Oral Mucositis

RAMtherapeutics is developing Triamdocaine™, an investigational product intended for study in cancer therapy–induced oral mucositis. Triamdocaine™ is being developed under an active FDA IND, and RAM’s current clinical-development focus is a 90-day Proof-of-Concept study.
Triamdocaine™ is an investigational drug. It has not been approved by FDA, and its safety and effectiveness have not been established. An active IND permits clinical investigation; it does not constitute FDA approval or endorsement.

About the Investigational Program

Oral mucositis is one of the most debilitating complications of cancer therapy. It occurs in 80–91% of head-and-neck cancer patients receiving radiation, with 56–66% developing severe disease depending on regimen. It interrupts treatment, drives hospitalization, and forces feeding-tube placement — and providers currently have no broadly effective pharmacologic option to prescribe.

RAM Pharmaceuticals is developing a patented direct-to-lesion dry-powder delivery process for localized intraoral administration. The investigational Triamdocaine™ program is designed to evaluate whether delivering therapy directly to affected tissue may address clinically important aspects of the condition. Its safety, effectiveness, dose, administration, and clinical utility have not been established.

RAMtherapeutics to pioneer a first-of-its-kind solution.

Expanding Horizons

RAM Pharmaceuticals is evaluating whether its delivery process may have potential research applications beyond oral mucositis, including conditions such as herpes zoster, commonly known as shingles, and genital herpes. These potential applications remain exploratory, and no safety or effectiveness conclusions have been established.

Innovating Supportive Cancer Care

RAMtherapeutics, a division of RAM Pharmaceuticals, is advancing next-generation solutions to support patients undergoing cancer treatment. Our lead investigational therapy, Triamdocaine™, is being developed under an active FDA IND with clinical studies scheduled to begin in Q1 2026.

Each year, approximately 650,000 cancer patients receive chemotherapy and 575,000 undergo radiation therapy in outpatient oncology clinics across the United States. Among patients with head and neck cancer, an estimated 60 % – 80 % experience severe oral complications such as oral mucositis during treatment. These side effects can cause intense discomfort, disrupt nutrition, and may even interrupt or delay therapy — significantly impacting quality of life and overall treatment continuity.

At RAMtherapeutics, our goal is to improve the supportive-care experience for these patients through novel delivery technologies that target the source of oral discomfort, helping maintain comfort and function during cancer therapy.

Key Elements of Triamdocaine™ Development

  1. Patient Comfort and Quality of Life Triamdocaine™ is being evaluated for its potential to support oral comfort and reduce localized irritation in patients undergoing radiation or chemotherapy. Our patented dry-powder delivery process enables precise, localized application designed to enhance tolerability and ease of use under professional supervision.
  2. Infection and Barrier Support The localized irritation associated with cancer therapy can create an entry point for bacteria and pathogens. RAMtherapeutics is developing solutions that may help maintain the integrity of the oral environment — a critical factor in reducing complications during treatment.
  3. Nutrition and Treatment Continuity By focusing on comfort and oral function, Triamdocaine™ aims to support the patient’s ability to eat and maintain hydration, both vital for sustaining therapy adherence and overall wellness.
  4. Economic and Systemic Impact The management of oral discomfort related to cancer therapy costs the U.S. healthcare system hundreds of millions annually due to hospitalizations, nutritional support, and infection management. Supportive-care innovations that reduce this burden represent significant value for patients, providers, and payors alike.
 

Investment Outlook

  • Clinical development: Phase 2 study planned for initiation in Q1 2026
  • Regulatory status: Active FDA IND under RAMtherapeutics
  • Intellectual property: Patented delivery technology protected through 2039
  • Market opportunity: The global market for supportive-care therapies addressing oral complications of cancer treatment is projected to exceed USD 2.8 billion by 2033, growing at 7–8 % CAGR
  • Strategic positioning: First-in-class dry-powder delivery platform for localized comfort management in oncology

Forward Vision

RAMtherapeutics is building a pipeline at the intersection of oncology and comfort care — developing therapies that address critical gaps in patient support and advance the future of compassionate cancer care.
Triamdocaine™ is an investigational drug. It has not been approved by FDA, and its safety and effectiveness have not been established. An active IND permits clinical investigation; it does not constitute FDA approval or endorsement.
Scroll to Top